News

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.

Discover essential sun protection strategies from Dr. Susan Taylor, focusing on the impacts of UV, visible light, and personalized sunscreen choices.

A new comparative study evaluated positive outcomes from patient use of a gua sha versus a facial roller over 8 weeks of treatment.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Recent research outlined 5 subtypes of vitiligo that can be used to guide therapeutic choices.

Alys plans to conduct a phase 1/1b trial assessing the efficacy and safety of the mast cell selective c-Kit inhibitor in the CIndU subtype.

Aaron Farberg, MD, led a panel exploring the challenges of diagnosing and treating generalized pustular psoriasis and the promise of targeted therapies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

Discover the future of regenerative skincare with Skin Moderne’s groundbreaking Exosomes Regenerative Complex, a plant-derived innovation led by Dr. Frank Roesken, MD, PhD.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

This review of the latest dermatologic studies includes insights into skin improvement with injectable hyaluronic acid, burden of chronic spontaneous urticaria, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

Discover innovative insights from the JADE REAL study on flexible dosing of abrocitinib for managing moderate to severe atopic dermatitis.

Researchers found CU was associated with increased odds of developing anxiety, depression, PTSD, and substance use disorder, among other conditions.

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Treatment with rupatadine led to improvements in CSU and chronic inducible urticaria.

Discover the revolutionary Hydrafacial HydraFillic with Pep9 Booster, enhancing skin hydration and reducing fine lines with advanced peptide technology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.